Parker Waichman LLP Notes Judicial Panel on Multi-District Litigation's (JPML) Consolidation of Lawsuits Alleging that Hair Relaxers Marketed by L'Oreal USA Inc. and Others Causes Uterine, Ovarian, Endometrial and Other Cancers Primarily in Black Women
PORT WASHINGTON, N.Y., Feb. 8, 2023 /PRNewswire/ -- In an order issued on February 6, 2023, the JPML granted a request to consolidate cases involving allegations that hair relaxer products marketed by L'Oreal USA Inc. and others caused uterine, ovarian, endometrial, and other cancers in women.
Pursuant to the order, these cases, and others, will be consolidated before U.S. District Court Judge Mary M. Rowland in the Northern District of Illinois in Chicago as "All actions share common issues of fact regarding whether exposure to phthalates or other [endocrine-disrupting chemicals] causes injury to the reproductive system, whether and when defendants knew or should have known of the alleged risks posed by hair relaxer products, and whether defendants engaged in adequate testing and post-market surveillance."
Lawsuits have been filed in federal courts in many states including those in New York, California, Tennessee, Ohio, and Georgia, and Parker Waichman LLP expects many more to be filed in the upcoming days and months.
Filing a Hair Relaxer Claim
Parker Waichman LLP represents hundreds of women for conditions believed to have been caused by the use of hair relaxer products.
If you or a loved one have used hair relaxers and been diagnosed with uterine cancer, or ovarian or endometrial cancer, you could be entitled to receive substantial monetary compensation from the manufacturers of these products.
Parker Waichman LLP helps those who have suffered from defective products receive full monetary compensation. If you or a loved one have been diagnosed with uterine, ovarian or endometrial cancer that they believe was caused by the use of hair relaxer products, please call our law firm at 1-800-968-7529 or visit our website at www.yourlawyer.com.
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIOŽ (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...